Milea Timbergen

178 References 1 . Fletcher CDM, Bridge JA, PCWH, F M. World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of soft tissue and bone. Press: Lyon: IARC; 2013 2013. 2 . Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, et al. Desmoid-type fibromatosis and pregnancy: A multi-institutional analysis of recurrence and obstetric risk. Annals of Surgery. 2014;259(5):973-978. 3 . World Health Organization International Classification of Disease XH13Z3 Aggressive fibromatosis: World Health Organization; 2018 [updated June 18 2018. Available from: https://icd.who.int/browse11/l-m/en#/http ://id.who.int/icd/entity/1314962913. 4 . van Broekhoven DL, Grunhagen DJ, den Bakker MA, van Dalen T, Verhoef C. Time trends in the incidence and treatment of extra-abdominal and abdominal aggressive fibromatosis: a population-based study. Ann Surg Oncol. 2015;22(9):2817-2823. 5 . Penel N, Coindre JM, Bonvalot S, Italiano A, Neuville A, Le Cesne A, et al. Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. Eur J Cancer. 2016;58:90-96. 6 . Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. Eur J Cancer. 2017;83:125-131. 7 . Desmoid Tumor Working G. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. Eur J Cancer. 2020;127:96-107. 8 . Briand S, Barbier O, Biau D, Bertrand-Vasseur A, Larousserie F, Anract P, et al. Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. Journal of Bone and Joint Surgery - American Volume. 2014;96(8):631-638. 9 . Colombo C, Miceli R, Le Pechoux C, Palassini E, Honore C, Stacchiotti S, et al. Sporadic extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. European Journal of Cancer. 2015:186-192. 10 . Bonvalot S, Ternes N, Fiore M, Bitsakou G, Colombo C, Honore C, et al. Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought. Ann Surg Oncol. 2013;20(13):4096-4102. 11 . Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, et al. Management of sporadic desmoid-type fibromatosis: a European consensus approach based on patients’ and professionals’ expertise - a sarcoma patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. Eur J Cancer. 2015;51(2):127-136. 12 . Bonvalot S, Eldweny H, Haddad V, Rimareix F, Missenard G, Oberlin O, et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008;34(4):462-468. 13 . Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann Surg. 1999;229(6):866-873. 14 . Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Pechoux C, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16(9):2587-2593. 15 . Bonvalot S. NCT01801176 - Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/NCT01801176?cond=NCT01801176&rank=1 16 . Gronchi A. NCT02547831 -Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients ClinicalTrials.gov Available from: https://clinicaltrials.gov/ct2/show/ NCT02547831 6